Patiromer Limits Impact of RAAS Inhibitor-Related Hyperkalemia in HF

(MedPage Today) -- WASHINGTON -- Use of the potassium-binding agent patiromer (Veltassa) allowed more heart failure patients at risk for hyperkalemia to remain on optimal therapy with renin-angiotensin-aldosterone system inhibitors (RAAS), including...
Source: MedPage Today Nephrology - Category: Urology & Nephrology Source Type: news